Diabetic foot infections are a significant clinical challenge. A comprehensive approach, including novel antimicrobial therapies and drug delivery systems, is needed to improve outcomes and combat antimicrobial resistance.
The SGLT2 inhibitor empagliflozin significantly slows the progression of diabetic retinopathy in type 2 diabetes compared with dipeptidyl-peptidase 4 inhibitor treatment, but does not reduce incidence.
Managing diabetes in patients with acromegaly requires both acromegaly and hyperglycemia to be controlled. How should medical treatment be tailored if pituitary surgery is not fully successful?
Sequential oral metformin and glyburide is not noninferior to insulin for gestational diabetes with respect to the proportion of infants born large for gestational age.
Understand the link between diabetes and dementia-related disorders, planning for cognitive wellness, and the choice of therapy for patients with type 2 diabetes who have, or are at risk of, comorbid cognitive impairment.
With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report.
A patient with pancreatogenic diabetes developed life-threatening euglycemic ketoacidosis following re-exposure to an SGLT2 inhibitor and alcohol excess. Early renal replacement therapy was successful.
A deep dive into eight cases of patients with a Fontan circulation who were prescribed GLP-1 agonists for obesity or diabetes. Find out if the treatments were effective, and what effects they had on patient comorbidities and safety outcomes.
A 38-year-old woman underwent genetic testing for suspected Brugada syndrome, but a missense mutation in the LMNA gene and the presence of suggestive traits led to a diagnosis of familial partial lipodystrophy type 2.
Despite many recent advances in its management, type 1 diabetes remains a burden for those living with the condition.
Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.
The incidence of diabetic kidney disease (DKD) is rising annually. Diabetes leads to structural damage and dysfunction in the kidneys, clinically manifesting as progressive proteinuria and declining renal function, ultimately resulting in …
Pregnancy in women with Type 1 diabetes mellitus (T1DM) presents a complex clinical scenario characterized by the need for meticulous glycaemic control to ensure optimal maternal and fetal outcomes [ 1 ]. During pregnancy, the body undergoes …
Recent studies emphasize the beneficial effects of exercise on diabetic cardiomyopathy (DCM), adding to the growing body of evidence that underscores the role of exercise in improving health outcomes. Despite this, a notable gap persists in the …
Insulin resistance is a condition characterized by the attenuated biological response in the presence of normal or elevated insulin level and therefore is characterized by the impaired sensitivity to insulin and impaired glucose disposal and …
Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills.
Stay up to date with the rapidly changing CGM landscape. Learn how to implement and integrate CGM into diabetes management to improve patient care and outcomes.
Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.
This program is not available to users in the UK and US.
More than 10.5% of the world’s adult population has diabetes today, according to an epidemiological study conducted in 2021. China, India, and Pakistan have the highest prevalence of diabetes among people aged 20–79. This trend is expected to …
Screening for diabetic retinopathy (DR) is recommended as one of the key strategies to reduce global blindness [ 1 ]. Despite worldwide screening, DR is still the leading cause of global blindness among the working population and projected to be so …
Type 2 diabetes (T2D) is a growing health concern worldwide and is one of the top 10 causes of death and disability globally [ 1 , 2 ]. In the US adult population, the estimated prevalence of diabetes in 2021 was over 38 million, and 90–95% of …
Despite great advances in the treatment of diabetes mellitus, diabetic nephropathy is still the leading cause of end-stage kidney disease (ESKD) in Western countries [ 1 ]. In a long-term follow up of patients diagnosed with type 1 diabetes …
The SGLT2 inhibitor empagliflozin significantly slows the progression of diabetic retinopathy in type 2 diabetes compared with dipeptidyl-peptidase 4 inhibitor treatment, but does not reduce incidence.
The SGLT2 inhibitor empagliflozin significantly slows the progression of diabetic retinopathy in type 2 diabetes compared with dipeptidyl-peptidase 4 inhibitor treatment, but does not reduce incidence.
Diabetic foot infections are a significant clinical challenge. A comprehensive approach, including novel antimicrobial therapies and drug delivery systems, is needed to improve outcomes and combat antimicrobial resistance.
Sequential oral metformin and glyburide is not noninferior to insulin for gestational diabetes with respect to the proportion of infants born large for gestational age.
